Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119307 | 0.91 | SCD (0.39) | CYP11B2ADORA2BSCDCYP2C9NAMPT | |
| SCHEMBL31119280 | 0.86 | ALDH1A1 (0.41) | TP53TSHRCYP2C9KDM4EALDH1A1 | |
| SCHEMBL31119324 | 0.85 | GLS (0.34) | TP53TSHRPIK3CAMAPK1 | |
| SCHEMBL31119251 | 0.84 | CDK4 (0.33) | CYP11B2CYP11B1TP53TSHRSCD | |
| SCHEMBL31119261 | 0.82 | KDM5A (0.40) | — | |
| SCHEMBL31119267 | 0.82 | KDM5A (0.40) | — | |
| SCHEMBL31119306 | 0.82 | SOST (0.38) | CYP11B2CYP11B1TP53TSHRPIK3CA | |
| SCHEMBL31119308 | 0.81 | FBP1 (0.41) | TP53TSHRMTNR1AMTNR1BKDM4E | |
| SCHEMBL31119300 | 0.81 | MAP4K4 (0.38) | CYP11B2CYP11B1ADORA2BPIK3CAMAPK1 | |
| SCHEMBL31119262 | 0.81 | SCD (0.39) | CYP11B2ADORA2BSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683919-A1 | VANIN-1 INHIBITORS | Athos Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024196841-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | CYP11B2 3271/4885CYP11B1 2590/4885ADORA2B 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.